Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
AIDS and Behavior
Erschienen in: AIDS and Behavior 11/2016

12.02.2016 | Original Paper

What Time is it? Adherence to Antiretroviral Therapy in Ethiopia

verfasst von: Yordanos M. Tiruneh, Ira B. Wilson

Erschienen in: AIDS and Behavior | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

This study assessed adherence to antiretroviral therapy (ART) among people living with HIV/AIDS in Ethiopia and explored the sociocultural context in which they relate to their regimen requirements. Data were collected through semi-structured in-depth interviews with 105 patients on ART and observations held at the study clinic. We analyzed data using both qualitative and quantitative methods. Our findings indicate that study participants are highly adherent to dose but less adherent to dose schedule. Strict dose time instructions were reported as stressful and unrealistic. The discrepancy between adherence to dose and dose schedule could be explained by time perception, difficulty with the strictness of medication regimens, or beliefs about dose timing adherence. Care providers should acknowledge the complexities of medication practices and engage in shared decision-making to incorporate patients’ perspectives and identify effective interventions.
Literatur
1.
Mukherjee JS, Ivers L, Leandre F, Farmer P, Behforouz H. Antiretroviral therapy in resource-poor settings: decreasing barriers to access and promoting adherence. J Acquir Immune Defic Syndr. 2006;43:S123–6.CrossRefPubMed
2.
Boyd MA, Cooper DA. Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research. AIDS. 2007;21:S55–63.CrossRefPubMed
3.
McNeil DG. Africans outdo US Patients in following AIDS therapy. New York Times. 2003.
4.
Gill C, Hamer D, Simon J, Thea D, Sabin L. No room for complacency about adherence to antiretroviral therapy in Sub-saharan Africa. AIDS. 2005;19(12):1243–9.CrossRefPubMed
5.
Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19:658–65.CrossRefPubMed
6.
Ware NC, Idoko J, Kaaya S, Biraro IA, Wyatt MA, Agbaji O, et al. Explaining adherence success in Sub-saharan Africa: an ethnographic study. Plos Med. 2009;6:39–47.CrossRef
7.
Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.CrossRefPubMed
8.
Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med. 2000;50:1599–605.CrossRefPubMed
9.
Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357–66.CrossRefPubMed
10.
Kalichman S, Cherry C, White D, Ml Jones, Grebler T, Kalichman M, et al. Sexual HIV transmission and antiretroviral therapy: a prospective cohort study of behavioral risk factors among men and women living with HIV/AIDS. Ann Behav Med. 2011;42(1):111–9.CrossRefPubMed
11.
Lima VD, Harrigan R, Bangsberg, Hogg RS, Gross R, Yip B, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr (1999). 2009;50(5):529–36.CrossRef
12.
Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, et al. Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20:223–31.CrossRefPubMed
13.
Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012;26(8):929–38.CrossRefPubMed
14.
Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. Plos Med. 2006;3:2039–64.
15.
Hawkins C, Murphy R. Adherence to antiretroviral therapy in resource-limited settings: everything matters. AIDS. 2007;21(8):1041–2.CrossRefPubMed
16.
Kagee A, Remien RH, Berkman A, Hoffman S, Campos L, Swartz L. Structural barriers to ART adherence in Southern Africa: challenges and potential ways forward. Global Public Health. 2011;6:83–97.CrossRefPubMedPubMedCentral
17.
Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor–based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564–73.CrossRefPubMed
18.
Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in Sub-saharan Africa and North America: a meta-analysis. J Am Med Assoc. 2006;296(6):679–90.CrossRef
19.
Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to 3 years on treatment in Sub-saharan Africa, 2007–2009: systematic review. Tropical Med Int Health. 2010;15(s1):1–15.CrossRef
20.
Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix M-L, Le Tiec C, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural Northwestern Uganda. BMC Infect Dis. 2009;9(1):81.CrossRefPubMedPubMedCentral
21.
Soria A, Porten K, Fampou-Toundji J-C, Galli L, Mougnutou R, Buard V, et al. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a cameroonian cohort of HIV type-1-infected patients. Antiviral Therapy. 2009;14:339–47.PubMed
22.
23.
Johannessen A, Naman E, Kivuyo SL, Kasubi MJ, Holberg-Petersen M, Matee MI, et al. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis. 2009;9:108.CrossRefPubMedPubMedCentral
24.
Sankar AP, Nevedal DC, Neufeld S, Luborsky MR. What is a missed dose? Implications for construct validity and patient adherence. AIDS Care. 2007;19:775–80.CrossRefPubMedPubMedCentral
25.
Reynolds NR. Adherence to antiretroviral therapies: state of the science. Curr HIV Res. 2004;2:207–14.CrossRefPubMed
26.
27.
Schönnesson LN, Williams ML, Ross MW, Bratt G, Keel B. Factors associated with suboptimal antiretroviral therapy adherence to dose, schedule, and dietary instructions. AIDS Behav. 2007;11(2):175–83.CrossRef
28.
Gill CJ, Sabin LL, Hamer DH, Keyi X, Jianbo Z, Li T, et al. Importance of dose timing to achieving undetectable viral loads. AIDS Behav. 2010;14(4):785–93.CrossRefPubMed
29.
Liu H, Miller LG, Hays RD, Golin CE, Wu T, Wenger NS, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006;41(3):315–22.CrossRefPubMed
30.
Lu M, Safren SA, Skolnik PR, Rogers WH, Coady W, Hardy H, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2008;12(1):86–94.CrossRefPubMed
31.
Genberg BL, Wilson IB, Bangsberg DR, Arnsten J, Goggin K, Remien RH, et al. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS. 2012;26(11):1415–23.CrossRefPubMedPubMedCentral
32.
Peltzer K, Preez N, Ramlagan S, Fomundam H. Use of traditional complementary and alternative medicine for HIV patients in Kwazulu-natal, South Africa. BMC Public Health. 2008;8:255.CrossRefPubMedPubMedCentral
33.
Ware N, Wyatt M, Tugenberg T. Social relationships, stigma and adherence to antiretroviral therapy for HIV/AIDS. AIDS Care. 2006;18:904–10.CrossRefPubMed
34.
Vervoort S, Borleffs J, Hoepelman A, Grypdonck M. Adherence in antiretroviral therapy: a review of qualitative studies. AIDS. 2007;21:271–81.CrossRefPubMed
35.
Goudge J, Ngoma B. Exploring antiretroviral treatment adherence in an urban setting in south africa. J Public Health Policy. 2011;32(S1):S52–64.CrossRefPubMed
36.
Denison JA, Koole O, Tsui S, Menten J, Torpey K, van Praag E, et al. Incomplete adherence among treatment-experienced adults on antiretroviral therapy in Tanzania, Uganda and Zambia. AIDS. 2015;29(3):361–71.CrossRefPubMedPubMedCentral
37.
Merten S, Kenter E, McKenzie O, Musheke M, Ntalasha H, Martin-Hilber A. Patient-reported barriers and drivers of adherence to antiretrovirals in Sub-saharan Africa: a meta-ethnography. Trop Med Int Health. 2010;15:16–33.CrossRefPubMed
38.
Robinson JH, Callister LC, Berry JA, Dearing KA. Patient-centered care and adherence: definitions and applications to improve outcomes. J Am Acad Nurse Pract. 2008;20(12):600–7.CrossRefPubMed
39.
Govindasamy D, Meghij J, Negussi EK, Baggaley RC, Ford N, Kranzer K. Interventions to improve or facilitate linkage to or retention in pre-ART (HIV) care and initiation of ART in low- and middle-income settings—a systematic review. J Int AIDS Soc. 2014;17(1):19032.CrossRefPubMedPubMedCentral
40.
Nachega JB, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Current Opin HIV AIDS. 2010;5:70–7.CrossRefPubMed
41.
Sankar A, Golin C, Simoni J, Luborsky M, Pearson C, Natl Inst Drug A. How qualitative methods contribute to understanding combination antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2006;43:S54–68.CrossRefPubMedPubMedCentral
42.
Simoni J, Kurth A, Pearson C, Pantalone D, Merrill J, Frick P. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10:227–45.CrossRefPubMedPubMedCentral
43.
Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care. 2000;12:255–66.CrossRefPubMed
44.
Strauss A, Corbin J. Basics of qualitative research techniques and procedures for developing grounded theory. Thousand Oaks: Sage; 1998.
45.
Mannheimer S, Thackeray L, Huppler Hullsiek K, Chesney M, Gardner EM, Wu AW, et al. A randomized comparison of two instruments for measuring self-reported antiretroviral adherence. AIDS Care. 2008;20(2):161–9.CrossRefPubMed
46.
Creswell J, Clark Plano V, Morales A. Qualitative research designs: selection and implementation. Couns Psychol. 2007;35:236–64.CrossRef
47.
Glaser B, Strauss A. The discovery of grounded theory: strategies for qualitative research. New York: Aldine; 1967.
48.
Starks H, Brown Trinidad S. Choose your method: a comparison of phenomenology, discourse analysis, and grounded theory. Qual Health Res. 2007;17:1372–80.CrossRefPubMed
49.
IBM. Statistical package for the social sciences (version 19.0). SPSS. Chicago: IBM; 2010.
50.
Tadios Y, Davey G. Antiretroviral treatment adherence and its correlates in Addis Ababa, Ethiopia. Ethiop Med J. 2006;44:237–45.PubMed
51.
Tiyou A, Belachew T, Alemseged F, Biadgilign S. Predictors of adherence to antiretroviral therapy among people living with HIV/AIDS in resource-limited setting of Southwest Ethiopia. AIDS Res Therapy. 2010;7:39. doi:10.​1186/​1742-6405-7-39.CrossRef
52.
Amberbir A, Woldemichael K, Getachew S. Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health. 2008;8:265.CrossRefPubMedPubMedCentral
53.
Chalker J, Andualem T, Minzi O, Ntaganira J, Ojoo A, Waako P, et al. Monitoring adherence and defaulting for antiretroviral therapy in 5 east African countries: an urgent need for standards. J Int Assoc Phys AIDS Care. 2008;7:193–9.CrossRef
54.
McCoy L. Time, self and the medication day: a closer look at the everyday work of ‘adherence’. Sociol Health Illn. 2009;31:128–46.CrossRefPubMed
55.
Conrad P. The meaning of medications—another look at compliance. Soc Sci Med. 1985;20:29–37.CrossRefPubMed
56.
Langebeek N, Gisolf EH, Reiss P, Vervoort SC, Hafsteinsdóttir TB, Richter C, et al. Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med. 2014;12:142.CrossRefPubMedPubMedCentral
57.
Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004;53:696–9.CrossRefPubMed
58.
Gourlay A, Wringe A, Birdthistle I, Mshana G, Michael D, Urassa M. “It is like that, we didn’t understand each other”: exploring the influence of patient-provider interactions on prevention of mother-to-child transmission of HIV service use in rural Tanzania. PLoS One. 2014;9(9):e106325.CrossRefPubMedPubMedCentral
59.
Assefa Y, Alebachew A, Lera M, Lynen L, Wouters E, Van Damme W. Scaling up antiretroviral treatment and improving patient retention in care: lessons from Ethiopia, 2005–2013. Glob Health. 2014;10:43. doi:10.​1186/​1744-8603-10-43.CrossRef
60.
WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: WHO, 2013.
61.
Epstein RM. The science of patient-centered care. J Fam Pract. 2000;49(9):805–7.PubMed
62.
Charles C, Gafni A, Whelan T. Decision-making in the physician–patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med. 1999;49(5):651–61.CrossRefPubMed
63.
Penn C, Watermeyer J, Evans M. Why don’t patients take their drugs? The role of communication, context and culture in patient adherence and the work of the pharmacist in HIV/AIDS. Patient Educ Couns. 2011;83(3):310–8.CrossRefPubMed
64.
Sandman L, Granger BB, Ekman I, Munthe C. Adherence, shared decision-making and patient autonomy. Med Health Care Philos. 2012;15:115–27.CrossRefPubMed
65.
Vermeire E, Hearnshaw H, Van Royen, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26:331–42.CrossRefPubMed
66.
Wilson IB, Fowler FJ, Cosenza CA, Michaud J, Bentkover J, Rana A, et al. Cognitive and field testing of a new set of medication adherence self-report items for HIV care. AIDS Behav. 2014;18(12):2349–58.CrossRefPubMed
67.
Feldman BJ, Fredericksen RJ, Crane PK, Safren SA, Mugavero MJ, Willig JH, et al. Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. AIDS Behav. 2013;17(1):307–18.CrossRefPubMedPubMedCentral
68.
Creswell J. Qualitative inquiry and research design. Second edition. California: Sage; 2007.
Metadaten
Titel
What Time is it? Adherence to Antiretroviral Therapy in Ethiopia
verfasst von
Yordanos M. Tiruneh
Ira B. Wilson
Publikationsdatum
12.02.2016
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 11/2016
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1322-0

Weitere Artikel der Ausgabe 11/2016

AIDS and Behavior 11/2016 Zur Ausgabe

Original Paper

Correlates of Combination Antiretroviral Adherence Among Recently Diagnosed Older HIV-Infected Adults Between 50 and 64 years

Original Paper

Assessing Adherence to Antiretroviral Therapy in a Rural Paediatric Cohort in KwaZulu-Natal, South Africa

Original Paper

The Acceptability and Perceived Usefulness of a Weekly Clinical SMS Program to Promote HIV Antiretroviral Medication Adherence in KwaZulu-Natal, South Africa

Original Paper

Factors Associated with Preference for Early Infant Male Circumcision Among a Representative Sample of Parents in Homa Bay County, Western Kenya

Original Paper

Substance Use and Adherence Among People Living with HIV/AIDS Receiving cART in Latin America

Original Paper

Validation of a New Three-Item Self-Report Measure for Medication Adherence

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise